BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oeda S, Takahashi H, Imajo K, Seko Y, Ogawa Y, Moriguchi M, Yoneda M, Anzai K, Aishima S, Kage M, Itoh Y, Nakajima A, Eguchi Y. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study. J Gastroenterol 2020;55:428-40. [PMID: 31654131 DOI: 10.1007/s00535-019-01635-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Lupsor-Platon M, Serban T, Silion AI, Tirpe A, Florea M. Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography. Cancers (Basel) 2020;12:E2778. [PMID: 32998257 DOI: 10.3390/cancers12102778] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Ni XX, Lian M, Wu HM, Li XY, Sheng L, Bao H, Miao Q, Xiao X, Guo CJ, Li H, Ma X, Hua J. Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases. World J Gastroenterol 2021; 27(1): 80-91 [PMID: 33505152 DOI: 10.3748/wjg.v27.i1.80] [Reference Citation Analysis]
3 Oeda S, Tanaka K, Oshima A, Matsumoto Y, Sueoka E, Takahashi H. Diagnostic Accuracy of FibroScan and Factors Affecting Measurements. Diagnostics (Basel) 2020;10:E940. [PMID: 33198092 DOI: 10.3390/diagnostics10110940] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
4 Kimura S, Tanaka K, Oeda S, Inoue K, Inadomi C, Kubotsu Y, Yoshioka W, Okada M, Isoda H, Kuwashiro T, Akiyama T, Kurashige A, Oshima A, Oshima M, Matsumoto Y, Kawaguchi A, Anzai K, Sueoka E, Aishima S, Takahashi H. Effect of skin-capsular distance on controlled attenuation parameter for diagnosing liver steatosis in patients with nonalcoholic fatty liver disease. Sci Rep 2021;11:15641. [PMID: 34341368 DOI: 10.1038/s41598-021-94970-3] [Reference Citation Analysis]
5 Campos-Murguía A, Ruiz-Margáin A, González-Regueiro JA, Macías-Rodríguez RU. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2020; 26(39): 5919-5943 [PMID: 33132645 DOI: 10.3748/wjg.v26.i39.5919] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
6 Mertens J, Van Gaal LF, Francque SM, De Block C. NAFLD in type 1 diabetes: overrated or underappreciated? Ther Adv Endocrinol Metab 2021;12:20420188211055557. [PMID: 34840719 DOI: 10.1177/20420188211055557] [Reference Citation Analysis]
7 Fujii H, Kawada N, Japan Study Group Of Nafld Jsg-Nafld. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E3863. [PMID: 32485838 DOI: 10.3390/ijms21113863] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
8 Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol 2022;18:55-66. [PMID: 34815553 DOI: 10.1038/s41574-021-00584-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sirli R, Sporea I. Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut-Offs to Use? Can J Gastroenterol Hepatol 2021;2021:6662760. [PMID: 33834008 DOI: 10.1155/2021/6662760] [Reference Citation Analysis]
10 Murayama K, Okada M, Tanaka K, Inadomi C, Yoshioka W, Kubotsu Y, Yada T, Isoda H, Kuwashiro T, Oeda S, Akiyama T, Oza N, Hyogo H, Ono M, Kawaguchi T, Torimura T, Anzai K, Eguchi Y, Takahashi H. Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. Diagnostics (Basel) 2021;11:132. [PMID: 33467114 DOI: 10.3390/diagnostics11010132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Zhang X, Mens MMJ, Abozaid YJ, Bos D, Darwish Murad S, de Knegt RJ, Ikram MA, Pan Q, Ghanbari M. Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study. Aliment Pharmacol Ther 2021;53:432-42. [PMID: 33244812 DOI: 10.1111/apt.16177] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Grąt K, Grąt M, Rowiński O. Usefulness of Different Imaging Modalities in Evaluation of Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines 2020;8:E298. [PMID: 32839409 DOI: 10.3390/biomedicines8090298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Selvaraj EA, Mózes FE, Jayaswal ANA, Zafarmand MH, Vali Y, Lee JA, Levick CK, Young LAJ, Palaniyappan N, Liu CH, Aithal GP, Romero-Gómez M, Brosnan MJ, Tuthill TA, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M; LITMUS Investigators. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. J Hepatol 2021:S0168-8278(21)00309-3. [PMID: 33991635 DOI: 10.1016/j.jhep.2021.04.044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
14 Petroff D, Blank V, Newsome PN, Shalimar, Voican CS, Thiele M, de Lédinghen V, Baumeler S, Chan WK, Perlemuter G, Cardoso AC, Aggarwal S, Sasso M, Eddowes PJ, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Cobbold JF, Naveau S, Lupsor-Platon M, Mueller S, Krag A, Irles-Depe M, Semela D, Wong GL, Wong VW, Villela-Nogueira CA, Garg H, Chazouillères O, Wiegand J, Karlas T. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol 2021;6:185-98. [PMID: 33460567 DOI: 10.1016/S2468-1253(20)30357-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
15 Cansanção K, Citelli M, Carvalho Leite N, López de Las Hazas MC, Dávalos A, Tavares do Carmo MDG, Peres WAF. Impact of Long-Term Supplementation with Fish Oil in Individuals with Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Placebo Controlled Clinical Trial. Nutrients 2020;12:E3372. [PMID: 33147705 DOI: 10.3390/nu12113372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Oeda S, Takahashi H, Imajo K, Seko Y, Kobayashi T, Ogawa Y, Moriguchi M, Yoneda M, Anzai K, Irie H, Sueoka E, Aishima S, Kage M, Itoh Y, Eguchi Y, Nakajima A. Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: Comparison between M and XL probes. Hepatol Res 2020;50:831-9. [PMID: 32337818 DOI: 10.1111/hepr.13508] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
17 Yu CS, Lin CH, Lin YJ, Lin SY, Wang ST, Wu JL, Tsai MH, Chang SS. Clustering Heatmap for Visualizing and Exploring Complex and High-dimensional Data Related to Chronic Kidney Disease. J Clin Med 2020;9:E403. [PMID: 32024311 DOI: 10.3390/jcm9020403] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
18 Chen B, Pan CQ. Non-Invasive Assessment of Fibrosis and Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease. Clin Res Hepatol Gastroenterol 2021;:101755. [PMID: 34311134 DOI: 10.1016/j.clinre.2021.101755] [Reference Citation Analysis]
19 Park J, Lee JM, Lee G, Jeon SK, Joo I. Quantitative Evaluation of Hepatic Steatosis Using Advanced Imaging Techniques: Focusing on New Quantitative Ultrasound Techniques. Korean J Radiol 2022;23:13-29. [PMID: 34983091 DOI: 10.3348/kjr.2021.0112] [Reference Citation Analysis]
20 Zenovia S, Stanciu C, Sfarti C, Singeap AM, Cojocariu C, Girleanu I, Dimache M, Chiriac S, Muzica CM, Nastasa R, Huiban L, Cuciureanu T, Trifan A. Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for the Diagnosis of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Diagnostics (Basel) 2021;11:787. [PMID: 33925569 DOI: 10.3390/diagnostics11050787] [Reference Citation Analysis]
21 Kage M, Aishima S, Kusano H, Yano H. Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Med Ultrason (2001) 2020;47:549-54. [PMID: 33136250 DOI: 10.1007/s10396-020-01061-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Zhou YJ, Gao F, Liu WY, Wong GL, Mahadeva S, Raihan Nik Mustapha N, Wang XD, Chan WK, Wong VW, Zheng MH. Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2021;54:470-80. [PMID: 34152626 DOI: 10.1111/apt.16487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
23 Honda Y, Yoneda M, Imajo K, Nakajima A. Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease.Int J Mol Sci. 2020;21. [PMID: 32516937 DOI: 10.3390/ijms21114039] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
24 Tavaglione F, De Vincentis A, Bruni V, Gallo IF, Carotti S, Tuccinardi D, Spagnolo G, Ciociola E, Mancina RM, Jamialahmadi O, D'Alessio R, Bottazzi B, Manfrini S, Picardi A, Perrone G, Pozzilli P, Caricato M, Vespasiani-Gentilucci U, Romeo S. Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery. Liver Int 2021. [PMID: 34890093 DOI: 10.1111/liv.15127] [Reference Citation Analysis]